HCV NS5A replication complex inhibitors. Part 4.1 optimization for genotype 1a replicon inhibitory activity

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 1976-1994

  St Laurent, Denis R ^a   Serrano Wu, Michael H ^a,b   Belema, Makonen ^a   Ding, Min ^a   Fang, Hua ^a   Gao, Min ^a   Goodrich, Jason T ^a   Krause, Rudolph G ^a   Lemm, Julie A ^a   Liu, Mengping ^a   Lopez, Omar D ^a   Nguyen, Van N ^a   Nower, Peter T ^a   O'Boyle, Donald R ^a   Pearce, Bradley C ^a   Romine, Jeffrey L ^a   Valera, Lourdes ^a   Sun, Jin Hua ^a   Wang, Ying Kai ^a   Yang, Fukang ^a   Yang, Xuejie ^a,c   Meanwell, Nicholas A ^a   Snyder, Lawrence B ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; DACLATASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PROLINAMIDE; PROTEINASE INHIBITOR; STILBENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE VIRAL DIARRHEA VIRUS; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETERMINATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; GENOTYPE; HEPATITIS C VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PESTIVIRUS; PROTEIN CONFORMATION; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROTEASE INHIBITORS; REPLICON; RNA REPLICASE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84879689219     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301796k     Document Type: Article

References (73)

1. Paper 3 in this series: Lopez, O. D.; Nguyen, V. N.; St. Laurent, D. R.; Belema, M.; Serrano-Wu, M. H.; Goodrich, J. T.; Yang, F.; Qiu, Y.; Ripka, A. S.; Nower, P. T.; Valera, L.; Liu, M.; O'Boyle, D. R., II; Sun, J.-H.; Fridell, R. A.; Lemm, J. A.; Gao, M.; Good, A. C.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 3: Discovery of potent analogs with distinct core topologies Bioorg. Med. Chem. Lett. 2013, 23, 779-784
2. Lavanchy, D. Evolving epidemiology of hepatitis C virus Clin. Microbiol. Inf. 2011, 17, 107-115
3. Pawlotsky, J.-M. The science of direct-acting antiviral and host-targeted agent therapy. A review Antiviral Ther. 2012, 17, 1109-1117
4. Thompson, A. J.; Locarnini, S. Direct-acting antiviral agents for the treatment of HCV. An editorial Antiviral Ther. 2012, 17, 1105-1107
5. Ghany, M. G.; Nelson, D. R.; Strader, D. B.; Thomas, D. L.; Seeff, L. B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 2011, 54, 1433-1444
6. Buehler, S.; Bartenschlager, R. New targets for the antiviral therapy of chronic hepatitis C Liver Int. 2012, 32 (Suppl. 1) 9-16
7. Sheridan, C. New Merck and Vertex drugs raise standard of care in hepatitis C Nat. Biotechnol. 2011, 29, 553-554
8. Cheng, K.-C.; Gupta, S.; Wang, H.; Uss, A. S.; Njoroge, G. F.; Hughes, E. Current drug discovery strategies for treatment of hepatitis C virus infection J. Pharm. Pharmacol. 2011, 63, 883-892
9. Yoshida, T.; Kondoh, M.; Yagi, K. Promising targets for anti-hepatitis C virus agents Curr. Med. Chem. 2011, 18, 1239-1244
10. Vermehren, J.; Sarrazin, C. New HCV therapies on the horizon Clin. Microbiol. Infect. 2011, 17, 122-134
11. Sulkowski, M. S.; Cooper, C.; Hunyady, B.; Jia, J.; Ogurtsov, P.; Peck-Radosavljevic, M.; Shiffman, M. L.; Yurdaydin, C.; Dalgard, O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 212-223
12. Brillanti, S.; Mazzella, G.; Roda, E. Ribavirin for chronic hepatitis C: and the mystery goes on Dig. Liver Dis. 2011, 43, 425-430
13. Kemp, W.; Roberts, S. Pegylated interferon and ribavirin for the treatment of chronic hepatitis C Clin. Med. Insights: Ther. 2011, 3, 137-150
14. Vezali, E.; Aghemo, A.; Colombo, M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis Clin. Ther. 2010, 32, 2117-2138
15. Bartenschlager, R.; Penin, F.; Lohman, V.; Andre, P. Assembly of infectious hepatitis C virus particles Trends Microbiol. 2011, 19, 95-103
16. Buehler, S.; Bartenschlager, R. Molecular mechanisms of hepatitis C virus (HCV) replication-implications for the development of antiviral drug s Z. Gastroenterol. 2011, 49, 836-844
17. Popescu, C.-I.; Rouille, Y.; Dubuisson, J. HCV replication and assembly: a play in one act Future Virol. 2011, 6, 985-995
18. Jones, D. M.; McLauchlan, J. Hepatitis C virus: assembly and release of virus particles J. Biol. Chem. 2010, 285, 22733-22739
19. Lo-Ten-Foe, J.; Richter, M.; Niesters, H. G. M. Hepatitis C Virus. In Molecular Detection of Human Viral Pathogens; Liu, D., Ed.; CRC Press: Boca Raton, FL, 2011; pp 189-200.
20. Targett-Adams, P.; Belda, O. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein Virus Res. 2012, 170, 1-14
21. Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E. Targeting the NS5A protein of HCV: an emerging option Drugs Future 2011, 691-711
22. Tan, S.-L.; Katze, M. G. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A Virology 2001, 284, 1-12
23. Lee, C. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy Arch. Pharmacol. Res. 2011, 34, 1403-1407
24. Najarro, P.; Mathews, N.; Cockerill, S. Hepatitis C; Tan, S.-L.; He, Y., Eds; Caister Academic Press; Norfolk, U.K., 2011; Chapter 14, pp 271-292.
25. Rong, L.; Perelson, A. S. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling Crit. Rev. Immunol. 2010, 30, 131-148
26. Ribeiro, R. M.; Li, H.; Wang, S.; Stoddard, M. B.; Learn, G. H.; Korber, B. T.; Bhattacharya, T.; Guedj, J.; Parrish, E. H.; Hahn, B. H.; Shaw, G. M.; Perelson, A. S. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate Pathogens 2012, 8, 1-13
27. Reviriego, C. Daclatasvir dihydrochloride Drugs Future 2011, 36, 735-739
28. Lok, A. S.; Gardiner, D. F.; Lawitz, E.; Martorell, C.; Everson, G. T.; Ghalib, R.; Reindollar, R.; Rustgi, V.; McPhee, F.; Wind-Rotolo, M.; Persson, A.; Zhu, K.; Dimitrova, D. I.; Eley, T.; Guo, T.; Grasela, D. M.; Pasquinelli, C. Preliminary study of two antiviral agents for hepatitis C genotype 1 N. Engl. J. Med. 2012, 366, 216-224
29. Chayama, K.; Takahashi, S.; Toyota, J.; Karino, Y.; Ikeda, K.; Ishikawa, H.; Watanabe, H.; McPhee, F.; Hughes, E.; Kumada, H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 2012, 55, 742-748
30. Poordad, F.; Lawitz, E.; Kowdley, K. V.; Cohen, D. E.; Podsadecki, T.; Siggelkow, S.; Heckaman, M.; Larsen, L.; Menon, R.; Koev, G.; Tripathi, R.; Pilot-Matias, T.; Bernstein, B. Exploratory study of oral combination antiviral therapy for hepatitis C N. Engl. J. Med. 2013, 368, 45-53
31. Gane, E. J.; Stedman, C. A.; Hyland, R. H.; Ding, X.; Svarovskaia, E.; Symonds, W. T.; Hindes, R. G.; Berrey, M. M. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N. Engl. J. Med. 2013, 368, 34-44
32. Poordad, F.; Lawitz, E.; Kowdley, K. V.; Cohen, D. E.; Podsadecki, T.; Siggelkow, S.; Heckaman, M.; Larsen, L.; Menon, R.; Koev, G.; Tripathi, R.; Pilot-Matias, T.; Bernstein, B. Exploratory study of oral combination antiviral therapy for hepatitis C N. Engl. J. Med. 2013, 368, 45-53
33. Gao, M.; Nettles, R. E.; Belema, M.; Snyder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-Wu, M. H.; Langley, D. R.; Sun, J.-H.; O'Boyle, D. R., II; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010, 465, 96-100
34. Romine, J. L.; St. Laurent, D. R.; Leet, J. E.; Martin, S. W.; Serrano-Wu, M. H.; Yang, F.; Gao, M.; O'Boyle, D. R., II; Lemm, J. A.; Sun, J.-H.; Nower, P. T.; Huang, X.; Deshpande, M. S.; Meanwell, N. A.; Snyder, L. B. Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes ACS Med. Chem. Lett. 2011, 2, 224-229
35. St. Laurent, D. R.; Belema, M.; Gao, M.; Goodrich, J.; Kakarla, R.; Knipe, J. O.; Lemm, J. A.; Liu, M.; Lopez, O. D.; Nguyen, V. N.; Nower, P. T.; O'Boyle, D. R., II; Qiu, Y.; Romine, J. L.; Serrano-Wu, M. H.; Sun, J.-H.; Valera, L.; Yang, F.; Yang, X.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides Bioorg. Med. Chem. Lett. 2012, 22, 6063-66
36. O'Boyle, D. R., II; Nower, P. T.; Lemm, J. A.; Valera, L.; Sun, J.-H.; Rigat, K.; Colonno, R.; Gao, M. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay Antimicrob. Agents Chemother. 2005, 49, 1346-1353
37. Sun, J. H.; Lemm, J. A.; O'Boyle, D. R., II; Racela, J.; Colonno, R.; Gao, M. Specific inhibition of bovine viral diarrhea virus replicase J. Virol. 2003, 77, 6753-6760
38. Scheel, T. K. H.; Gottwein, J. M.; Mikkelsen, L. S.; Jensen, T. B.; Bukh, J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α Gastroenterolgy 2011, 140, 1032-1042
39. Taliani, M.; Bianchi, E.; Narjes, F.; Fossatelli, M.; Urbani, A.; Steinkühler, C.; De Francesco, R.; Pessi, A. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates Anal. Biochem. 1996, 240, 60-67
40. Lohman, V.; Korner, F.; Koch, J.-O..; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113
41. Potential conformational differences between caps were investigated using a mixed torsional/low mode sampling protocol within Macromodel [Schrodinger, Maestro, version 9.2, OPLS2005 FF, water solvent]. An overlay [rmsd minimized proline ring] of full length compound 4 with a truncated version showed maintenance of symmetry and convergence on the conformational minimum.
42. Brameld, K. A.; Kuhn, B.; Reuter, D. C.; Stahl, M. Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis J. Chem. Inf. Model. 2008, 48, 1-24
43. Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology J. Med. Chem. 2013, 56, 1363-1388
44. 72 showed no significant changes. Moreover, the literature includes examples of analogues containing both 2-chloropyridine and 2-fluoropyridine moieties where enzymatic data were consistent in replicon, again indicating stability to assay conditions. See McGowan, D.; Nyanguile, O.; Cummings, M. D.; Vendeville, S.; Vandyck, K.; Van den Broeck, W.; Boutton, C. W.; De Bondt, H.; Quirynen, L.; Amssoms, K.; Bonfanti, J.-F.; Last, S.; Rombauts, K.; Tahri, A.; Hu, L.; Delouvroy, F.; Vermeiren, K.; Vandercruyssen, G.; Van der Helm, L.; Cleiren, E.; Mostmans, W.; Lory, P.; Pille, G.; Van Emelen, K.; Fanning, G.; Pauwels, F.; Lin, T.-I.; Simmen, K.; Raboisson, P. 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase Bioorg. Med. Chem. Lett. 2009, 19, 2492-2496
45. For examples, see the following: Serrano-Wu, M.; Belema, M.; Snyder, L. B.; Meanwell, N. A.; St. Laurent, D. R.; Kakarla, R.; Nguyen, V. N.; Qiu, Y.; Yang, X.; Leet, J. E.; Gao, M.; O'Boyle, D. R., II; Lemm, J. A.; Yang, F. Preparation of Proline Stilbenediamine Amides and Related Compounds as Inhibitors of HCV Replication. US-20060276511 A1, December 7, 2006.
46. Gesquiere, J.-C. 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ). In e-EROS: Encyclopedia of Reagents for Organic Synthesis; John Wiley & Sons: New York, 2001.
47. Belleau, B.; Malek, G. A convenient reagent for peptide synthesis J. Am. Chem. Soc. 1968, 90, 1651-1652
48. Srinivasan, N.; Yurek-George, A.; Ganesan, A. Rapid deprotection of N -Boc amines by TFA combined with freebase generation using basic ion-exchange resins Mol. Diversity 2005, 9, 291-293
49. Belema, M.; Nguyen, V. N.; Serrano-Wu, M.; St. Laurent, D. R.; Qiu, Y.; Ding, M.; Meanwell, N. A.; Snyder, L. B. Preparation of Biarylacetylenes and Biheteroarylacetylenes End-Capped with Amino Acid or Peptide Derivatives as Hepatitis C Virus Inhibitors. WO-2010039793 A1, April 8, 2010.
50. Lopez, O. D.; St. Laurent, D. R.; Goodrich, J.; Romine, J. L.; Serrano-Wu, M.; Yang, F.; Kakarla, R.; Yang, X.; Qiu, Y.; Snyder, L. B. Preparation of Biphenylheterocycles End-Capped with Amino Acid or Peptide Derivatives as Hepatitis C Virus Inhibitors. WO-2011082077 A1, July 7, 2011.
51. Bachand, C.; Belema, M.; Deon, D. H.; Good, A. C.; Goodrich, J.; James, C. A.; Lavoie, R.; Lopez, O. D.; Martel, A.; Meanwell, N. A.; Nguyen, V. N.; Romine, J. L.; Ruediger, E. H.; Snyder, L. B.; St. Laurent, D. R.; Yang, F.; Langley, D. R.; Wang, G.; Hamann, L. G. Preparation of Biphenyls and Biheteroaryls End-Capped with Amino Acid or Peptide Derivatives as Hepatitis C Virus Inhibitors. WO-2008021927 A2/A3, February 21, 2008.
52. For the synthesis of N -PhAc- l -proline, see the following: Gudasheval, T. A.; Voronina, T. A.; Ostrovskaya, R. U.; Rozantsevl, G. G.; Vasilevichl, N. I.; Trofimov, S. S.; Kravchenko, E. V.; Skoldinov, A. P.; Seredenin, S. B. Synthesis and antiamnesic activity of a series of IV-acylprolyl-containing dipeptides Eur. J. Med. Chem. 1996, 31, 151-157
53. Goyal, N. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI·HCl) Synlett 2010, 2, 335-336
54. El-Faham, A.; Albericio, F. Peptide coupling reagents, more than a letter soup Chem. Rev. 2011, 111, 6557-6602
55. Mascitti, V. Stille Coupling. In Name Reactions for Homologations; Li, J. J., Ed.; Wiley: Hoboken, NJ, 2009; Part 1, pp 133-162.
56. Wolfe, J. P.; Nakhla, J. S. The Suzuki Reaction. In Name Reactions for Homologations; Li, J. J., Ed.; Wiley: Hoboken, NJ, 2009; Part 1, pp 163-184.
57. Suzuki, A. Cross-coupling reactions of organoboranes: an easy way to construct C-C bonds (Nobel Lecture) Angew. Chem., Int. Ed. 2011, 50, 6722-6737
58. Wang, X. A.; Sun, L.-Q.; Sit, S.-Y.; Sin, N.; Scola, P. M.; Hewawasam, P.; Good, A. C.; Chen, Y.; Campbell, J. A. Preparation of Peptides as Hepatitis C Virus Inhibitors. WO-2003099274 A1, December 4, 2003.
59. Adapted from the following: Burgess, L. The preparation of immunosuppressant SR-31747 Synth. Commun. 1997, 27, 2181-2191
60. Adapted from the following: Chen, F.; Hsiao-Wei Tsui, V.; Cuong, L.; Flygare, J. A.; Pyrrolidine inhibitors of LAP. US-20060167066 A1, July 27, 2006.
61. Sundermeier, M.; Zapf, A.; Beller, M.; Sans, J. A new palladium catalyst system for the cyanation of aryl chlorides Tetrahedron Lett. 2001, 42, 6707-6710
62. Kirby, G. W.; Tan, S. L.; Uff, B. C. Cyanochlorination and cyanogenation of isoquinoline Chem. Commun. 1969, 1075
63. Eloy, F.; Deryckere, A. Synthesis of isocarbostyrils and 1-chloroisoquinolines Helv. Chim. Acta 1969, 52, 1755-62
64. Roe, A.; Trague, C. E., Jr. The preparation of heterocyclic fluorine compounds by the Schiemann reaction. III. Some monofluoroisoquinolines J. Org. Chem. 1951, 73, 687-688
65. Neumeyer, J. L.; Weinhardt, K. K. Isoquinolines. 1. 3-Amino- and 3-fluoroisoquinoline derivatives as potential antimalarials J. Med. Chem. 1970, 13, 613
66. Modified from the following: Sasaki, K.; Tsurumori, A.; Hirota, T. Polycyclic N-heterocyclic compounds. Part 52. One-step synthesis of imidazo[1,5- a ]pyridines, imidazo[1,5- a ]quinolines and imidazo[1,5- a ]-isoquinolines by Vilsmeier reactions of pyridine-2-carbonitriles, quinoline-2-carbonitriles and isoquinoline-1-carbonitriles J. Chem. Soc., Perkin Trans. 1 1998, 3851-3856
67. Sakamoto, T.; Kanda, S.; Nishimura, S.; Yamanaka, H. Site-selectivity in the cyanation of 3-substituted pyridine 1-oxides with trimethylsilanecarbonitrile Chem. Pharm. Bull. 1985, 33, 565-571
68. Christen, D. P. Mitsunobu Reaction. In Name Reactions for Homologations; Li, J. J., Ed.; Wiley: Hoboken, NJ, 2009; Part 2, pp 671-748.
69. But, T. Y. S.; Toy, P. H. The Mitsunobu reaction: origin, mechanism, improvements, and applications Chemistry-Asian J. 2007, 2, 1340-1355
70. Meagher, K. L.; Mewshaw, R. E.; Evrard, D. A.; Zhou, P.; Smith, D. L.; Scerni, R.; Spangler, T.; Abulhawa, S.; Shi, X.; Schechter, L. E.; Andree, T. H. Studies towards the next generation of antidepressants. Part 1: Indolylcyclohexylamines as potent serotonin reuptake inhibitors Bioorg. Med. Chem. Lett. 2001, 11, 1885-1888
71. Modified from the following: Hamada, Y.; Takeuchi, I.; Matsuoka, H. Syntheses of nitrogen-containing heterocyclic compounds. XV. The Reissert reaction of 1,6-naphthyridine Chem. Pharm. Bull. 1970, 18, 1026-1033
72. Miyashita, A.; Suzuki, Y.; Ohta, K.; Higashino, T. Preparation of heteroarenecarbonitriles by reaction of haloheteroarenes with potassium cyanide catalyzed by sodium p -toluenesulfinate Heterocycles 1994, 39, 345-355
73. Song, Z.; Mertzman, M.; Hughes, D. L. Improved synthesis of quinaldines by the Skraup reaction J. Heterocycl. Chem. 1993, 30, 17-21